VIVUS Announces Scientific Presentations

        Print
| Source: VIVUS, Inc.

MOUNTAIN VIEW, Calif., June 15, 2013 (GLOBE NEWSWIRE) -- VIVUS,Inc. (Nasdaq:VVUS), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced the following scientific presentations:

Conference

ENDO 2013: The Endocrine Society's 95th Annual Meeting and Expo

June 15-18, 2013

Moscone Center, San Francisco, CA

Date/Time

Poster Presentation Date: Saturday, June 15th, 2013, 1:45-3:45pm

Session Location: Expo Hall, Moscone Center

Poster Number: SAT-663

Abstract Number: 3585

Presentation Title

Improvements in Glycemic Parameters Associated With Magnitude of Weight Loss in Overweight/Obese Subjects Receiving Phentermine and Topiramate Extended-Release Over 2 Years

Authors: Lawrence J. Cheskin, MDa; Charles H. Bowden, MDb

Affiliations:
aJohns Hopkins Bloomberg School of Public Health, and Johns Hopkins Weight Management Center, Baltimore, MD
bVIVUS, Inc., Mountain View, CA

Conference

ESH 2013: 23rd European Meeting on Hypertension and Cardiovascular Protection

June 14-17, 2013

Mico Milano Congressi, Milan, Italy

Date/Time

Oral Presentation Date:  Monday, June 17th, 2013, 9:20-9:30

Session Location:  Red Hall, Mico Milano Congressi

Presentation Title

Improvements in Cardiometabolic Parameters as a Function of Magnitude of Weight Loss in Subjects With Hypertension Treated With Phentermine and Topiramate Extended-Release (PHEN/TPM ER)

Authors: Samuel Klein, MDa; Hermann Toplak, MDb; Roman V. Dvorak, MD, PhDc

Affiliations:
aWashington University Medical School, St. Louis, MO, USA
bMedical University of Graz, Graz, Austria
cVIVUS, Inc., Mountain View, CA, USA

Conference

ESH 2013: 23rd European Meeting on Hypertension and Cardiovascular Protection

June 14-17, 2013

Mico Milano Congressi, Milan, Italy

Date/Time

Oral Presentation Date:  Monday, June 17th, 2013, 17:50-18:00

Session Location: Blue Hall, Mico Milano Congressi

Presentation Title

Changes in Hypertension Status Associated With Phentermine and Topiramate Extended-Release Over 108 Weeks

Authors: Jens Jordan, MDa; Krzysztof Narkiewicz, MD, PhDb; Wesley W. Day, PhDc

Affiliations:
aInstitute of Clinical Pharmacology, Hannover Medical School, Hannover, Germany
bDepartment of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland
cVIVUS, Inc., Mountain View, CA, USA

About Qsymia

Qsymia® (phentermine and topiramate extended-release) capsules CIV is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ending December 31, 2012, as amended by the Form 10-K/A filed on April 30, 2013 and by the Form 10-K/A filed on June 12, 2013, and periodic reports filed with the Securities and Exchange Commission.

VIVUS, Inc.
Dana B. Shinbaum
Corporate Development
& Investor Relations


Investor Relations:
The Trout Group
Brian Korb

646-378-2923